Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2021-03-07
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies the side effects of sorafenib tosylate before and after
donor bone marrow transplantation in treating patients with acute myeloid leukemia. Sorafenib
tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth.